Phage on display  by unknown
Innovations 977 
Phage on display 
Dyax Corp. 
Big numbers are now almost routine 
in the pharmaceutical industry, as 
the screening of huge libraries of 
chemicals becomes a common 
event. Phage display, the technology 
that is at the core of Dyax Corp. 
(Cambridge, Massachusetts), is 
perhaps the most extreme example 
of the numbers game. 
The numbers in phage display 
come from the millions of different 
sequences that can be inserted in 
the gene for a coat protein of a 
phage (a virus that infects bacteria). 
The phage then obligingly make 
and display the hybrid proteins, and 
researchers can select phage with 
proteins that bind the specified 
target, with no need for microtiter 
plates, and the identity of the 
binding agent encoded in the viral 
DNA. The procedure sounds 
simple, and it is. “Phage display is 
so important in biological research 
because it’s very cheap,” says 
George Smith of the University of 
Missouri at Columbia. 
The genesis of an idea 
Smith was the first to use phage as a 
carrier of foreign sequences. 
Inspired by work showing that gene 
III of the filamentous phage fd was 
modular, he inserted foreign DNA 
into gene III. The hybrid phage 
were still capable of infecting 
bacteria, and the foreign sequences 
could be recognized by antibodies. 
“In 1984, I had tried to patent 
the idea of phage display without 
much of an idea of what we would 
use it for,” says Smith. Although his 
1985 Science paper suggested cloning 
genes using antibody-based 
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selection of hybrid phage, by this 
time he had failed to follow through 
with the patent process. A 1988 
paper in Gene outlined a practical 
approach to the cloning idea and 
suggested a new application. After a 
lunchtime discussion of Mario 
Geysen’s construction of libraries of 
synthetic peptides, Smith proposed 
inserting thousands or millions of 
different sequences into phage to 
make libraries that could be 
searched for novel binding 
activities. This is what we now call 
phage display, and Robert Ladner, 
now the Chief Scientific Officer at 
Dyax, had been having similar 
thoughts. “Ladner had the idea of 
phage display independently,” says 
Smith, “and he filed a patent a few 
weeks before the 1988 paper.” At 
around 350 pages, Ladner’s patent 
was no bedtime read. “We went 
through all of the steps in what 
some people thought of as 
nauseating detail,” he says. “But I 
don’t consider prolixity in this case 
to be a pejorative.” 
Certainly there is no abuse 
coming from Smith’s corner. 
“Ladner is a really inventive guy,” 
he says. “He’s had all these great 
ideas and is not well recognized for 
them.” 
Peptide therapeutics 
Since the main phage display 
patents were issued, Dyax has been 
busy licensing the technology, with 
over 25 companies licensed to date. 
The licenses are non-exclusive, 
so Dyax continues to develop 
therapeutics. Ladner has found 
several picomolar inhibitors of 
kallikrein and plasmin (proteases 
implicated in surgical bleeding) and 
human neutrophil elastase (hNE), a 
culprit in diseases including cystic 
fibrosis (CF), bronchitis, and 
emphysema. In CF, for example, the 
underlying defect in chloride 
channel functioning may cause 
increased recruitment of neutrophils 
to the lungs, and so excessive hNE 
production. The debris from the 
resultant proteolysis attracts more 
neutrophils and continues the cycle 
of inflammation and mucus 
production. “If you can break that 
cycle you wouldn’t have to dissolve 
the mucus,” says Ladner, “because 
you would prevent the production 
of the mucus in the first place.” 
Ladner uses small, well- 
structured proteins as scaffolds for 
the variant sequences, then adds the 
whole unit to gene III. Structural 
biologists have found that only a 
few critical amino acids specify the 
way that many proteins fold. This 
frustrates many a structure 
prediction, but allows Ladner to 
change many residues with few 
global consequences on the 
structure. “Because you can change 
the side-groups,” he says, “you can 
get binding to pretty much anything 
you want.” 
The scaffold for the hNE 
inhibitors is a Kunitz domain, the 
type of domain found in proteins 
such as bovine pancreatic trypsin 
inhibitor (BPTI). Other libraries 
have been based on cyclic peptides 
constrained by a single disulfide, 
and a trypsin inhibitor from the 
pumpkin Cucurbita maxima. 
The constrained sequences are 
preferable to unstructured peptides 
for a number of reasons: entropic 
change upon target binding is 
minimized, hydrophobic residues 
can be presented, binding 
characteristics are retained whether 
or not the sequence is embedded in 
the phage coat, the structure is 
easier to determine, and the same 
peptide sequences with different 
templates give libraries with 
different properties. 
But who wants peptides? 
The pharmaceutical industry, an 
enterprise based primarily on small, 
cell-permeant chemicals, was 
skeptical of the initial versions of 
combinatorial chemistry. That 
method has only become 
widespread with the generation of 
chemical rather than peptide 
libraries, but phage display is stuck 
with proteins and peptides. “Phage 
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display, where the structures are 
peptides, is not very well suited to 
drug development,” says Smith. 
“It’s pretty hard to turn a peptide 
into a drug.” 
But Ladner believes a change in 
attitude is in order. “Most US 
pharmaceutical companies are still 
run by chemists,” he says. “Even 
Amgen [a company that produces 
two protein pharmaceuticals with 
sales of -$2 billion per year] would 
rather have a pill than an injectable 
protein. We think they are 
excessively cautious. People don’t 
appreciate how effective proteins 
could be. There are some nightmare 
stories with the production of large, 
glycosylated proteins, but we stick 
with small proteins.” 
“If you’re not willing to use a 
protein [as a therapeutic],” he 
continues, “you don’t have to throw 
away phage display. This is by far 
the cheapest way to generate 
structure-activity information.” By 
looking at the shape of the best ten 
or one hundred peptide binders to a 
particular drug target, chemists can 
guess which small chemicals might 
bind most avidly to the same target. 
An affinity for separations 
Dyax was formed when the research 
outfit Protein Engineering Corp. 
(Cambridge, Massachusetts) merged 
with the pharmaceutical separations 
company Biotage, Inc. 
(Charlottesville, Virginia). The new 
entity remains very active in 
devising purification methods, a 
step which is often the most 
significant cost in the production of 
pharmaceuticals. Phage display is an 
ideal way to find an affinity ligand 
that makes purification more 
efficient. Standard chromatography 
can involve multiple steps with 
different types of columns, says 
Tom Ransohoff, Vice-president of 
Bioseparations. “What you’re 
looking for is that point in 
hydrophobicity-, charge-, and size- 
space where your protein is located. 
It’s very much an empirical, trial- 
and-error process, whereas we make 
molecules that bind your product 
and nothing else.” 
Dyax makes everything from 
laboratory-scale (l&mm diameter) 
cartridges to production-scale 
chromatography columns. The latter 
can process hundreds or even 
thousands of liters of extract in a 
single production run, and 
ultimately produce hundreds of 
kilograms of protein. Developing a 
new ligand can take several months, 
so this is usually done only at the 
scale-up stage. 
The results can be an 
extraordinarily good fit to the 
customer’s demands. “The beauty 
of phage display is that you can feed 
all the information in and make a 
system that suits your needs,” says 
Ladner. “It means that you can do 
more than people ever thought you 
could do with monoclonal 
antibodies,” the affinity agents most 
often used before the advent of 
phage display. As it is essentially an 
in vitro process, phage display can 
be done under harsh conditions 
including low or high pH, and the 
binding protein can be selected to 
bind at one pH, and not at another. 
The dissociation constant can be 
specified by varying the target 
concentration, and competitors that 
may interfere with binding in viva 
can be added to the in vitro binding 
reaction. Targets can be self- 
antigens, toxic, or essential proteins. 
The scaffold and the residues to 
be varied can be chosen depending 
on the target. The shape of the 
target may suggest that a flat, 
protruding, or helical segment 
would work best. This is an inexact 
science, however, and given the low 
cost of screening Dyax will often 
screen new targets with existing 
libraries. 
Displaying an image 
The location of a protein in the 
body can be a marker of disease. For 
example, peptides or small proteins 
that bind to hNE can be linked to 
radioisotopes and used to diagnose 
inflammatory bowel disease and 
pulmonary diseases involving 
inflammation. Animal trials of such 
agents are ongoing. Dyax is also 
searching for imaging agents that 
bind to blood clots. These could 
replace costly and invasive 
pulmonary angiograms. 
Beyond Dyax, beyond phage 
In partnerships, Dyax is using phage 
display in a wide variety of ways, 
from purification of vaccines (with 
Merck) or urokinase, an enzyme 
that may clear blocked catheters 
(with Argonex, Inc., Charlottesville, 
Virginia), to inhibition of 
intracellular signaling molecules 
(with Tularik, Inc., South San 
Francisco, California). 
The type of phage used has also 
diversified, with M13, lambda, T4 
and T7 all in use. The choice of 
phage depends on the insert size, 
and whether the researcher wants 
the protein to fold intracellularly 
(e.g., lambda) or extracellularly (e.g., 
M13). Only in the latter case will 
disulfides form properly. 
Phage can be used to display the 
entire complement of an 
individual’s antibodies; this 
complement can then be searched 
for a specific high affinity antibody. 
Reversing this situation, others have 
displayed epitopes from individuals 
with an infectious or autoimmune 
disease. These can then be probed 
with antibodies specific to the 
disease to identify the proteins 
responsible for the disease. 
According to Ladner, Dyax’s 
resources are limited, so large-scale 
trials of drugs in humans will require 
partnerships. “We’re not Merck: we 
have to watch what we’re doing,” he 
says. For the same reason other 
possible applications, such as binding 
environmental toxins, are also on 
hold. But a combination of licensing, 
research collaborations, and 
separations contracts is more than 
enough to keep things busy for now. 
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